Peptide Stacks by Goal: Recovery, Longevity, Libido, Fat Loss
A clinician's view of how the most-prescribed peptides combine — what works together, what doesn't, and what to skip entirely.
Peptide stacking is the practice of combining multiple peptides for synergistic effect. Done well, it amplifies results. Done poorly, it produces redundant cost and unnecessary risk.
Recovery stack
Goal: faster healing of musculoskeletal injury.
- BPC-157 250–500 mcg daily (localized tissue repair, angiogenesis) - TB-500 2 mg twice weekly (cell migration into injury site) - Optional: CJC-1295 + ipamorelin 100/100 mcg nightly (systemic recovery and sleep)
The first two address the local injury; the GH secretagogue stack supports systemic recovery and sleep quality.
Longevity stack
Goal: support healthy aging, cellular maintenance, and sleep.
- CJC-1295 + ipamorelin 100/100 mcg nightly (physiologic GH support) - NAD+ 100–250 mg weekly subcutaneous (cellular energy, sirtuin support) - Optional: thymosin alpha-1 1.6 mg twice weekly (immune resilience)
This stack focuses on the biological systems that decline most predictably with age: GH/IGF-1 signaling, mitochondrial function, and immune competence.
Libido stack
Goal: address sexual function with mechanisms outside the vascular pathway.
- PT-141 (bremelanotide) 1.75 mg subcutaneous as needed (central nervous system mechanism) - Optional: hormone optimization first, peptide second — low testosterone in men and low estradiol or testosterone in women should be addressed before adding PT-141
PT-141 works on the brain, not the blood vessels. It is the appropriate first choice when desire is the issue and traditional PDE5 inhibitors are insufficient or off-mechanism.
Fat loss stack
Goal: support body recomposition during a caloric deficit.
- AOD-9604 300 mcg daily subcutaneous (fragment of GH with lipolytic effect) - Optional: tesamorelin 1–2 mg daily subcutaneous (visceral fat reduction in selected patients)
For most patients, GLP-1 therapy is a more effective primary intervention. Fat-loss peptides are best positioned as adjuncts during a deficit phase, not as replacements for caloric or pharmacological control of intake.
What we don't stack
Multiple GH secretagogues simultaneously (CJC + ipamorelin + sermorelin) — there's no benefit to triple-stacking on the same pathway. Untested combinations with no clinical or mechanistic rationale. Anything where the patient cannot articulate why each component is in the protocol.
Sources & references
Peer-reviewed studies, clinical guidelines, and regulatory documents used to write this article.
- 1.Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6:45-53.— Sexual Medicine Reviews, 2018.
- 2.Sikiric P et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy. Curr Pharm Des. 2018;24:1962-1973.— Current Pharmaceutical Design, 2018.
- 3.Stanley TL et al. Effects of Tesamorelin on Visceral Fat and Liver Fat. JAMA. 2014;312:380-389.— Journal of the American Medical Association, 2014.
How this article was written: Researched and drafted by the Valora Rx editorial team using current peer-reviewed literature and clinical practice guidelines from bodies including the Endocrine Society, AUA, NAMS, ACOG, and FDA. This article is informational and is not a substitute for individualized medical advice from your physician. Read our editorial standards →
